Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 329 participants.

Also called NCT02334488

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 329 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02334488
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02334488. Randomized; no masking; primary purpose treatment. Start 2014-12-11 (actual); primary completion 2019-05-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study Evaluating the Benefit of Two Immunosuppressive Strategies on Renal Function
Intervention (Drug)
Everolimus
Intervention (Drug)
Tacrolimus
Intervention (Drug)
Mycophenolate sodium
Lead sponsor
Poitiers University Hospital (class: other)

Record details

Record id
cardio:ct-nct02334488
Content hash
6f372183ef55be45c12497e6124df0fb520c00e0a2bac06c7af296bfba3d6533